Cancer deaths are on the decline again, according to the American Cancer Society (ACS).
Between 1991 and 2006, the rates dropped 21.0% among men and 12.3% among women, resulting in an estimated 767,000 fewer deaths from cancer since the 1990s.
The society published the stats in its annual report on cancer statistics in their journal CA: A Cancer Journal for Clinicians. They credit the decline to three factors:
Incidences of cancer also appear to be on the decline, having decreased 1.3% per year among men (from 2000 to 2006) and 0.5% per year among women (from 1998 to 2006).
For a longer write-up of the report from the ACS press room, go here.
For the full report, go to Cancer Statistics, 2010.
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...